Stock Traders Purchase High Volume of Disc Medicine Put Options (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON) saw some unusual options trading on Monday. Investors bought 5,395 put options on the company. This represents an increase of 405% compared to the typical volume of 1,068 put options.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $120.00 price objective on shares of Disc Medicine in a report on Thursday, September 10th. Wedbush reissued an “outperform” rating and set a $100.00 target price on shares of Disc Medicine in a report on Thursday, September 10th. Morgan Stanley restated an “overweight” rating and issued a $90.00 price target on shares of Disc Medicine in a research report on Monday, August 17th. Wells Fargo & Company increased their price target on Disc Medicine from $79.00 to $86.00 and gave the company an “overweight” rating in a research note on Wednesday, September 16th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $128.00 target price on shares of Disc Medicine in a research note on Thursday, September 10th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.40.

Insider Transactions at Disc Medicine

In related news, CEO John D. Quisel sold 33,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the sale, the chief executive officer owned 226,064 shares in the company, valued at $17,892,965.60. The trade was a 12.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kevin Bitterman sold 49,164 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $80.17, for a total value of $3,941,477.88. Following the sale, the director owned 13,499 shares in the company, valued at $1,082,214.83. This represents a 78.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 131,221 shares of company stock valued at $10,239,760 over the last quarter. 3.76% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its holdings in shares of Disc Medicine by 191.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock valued at $73,280,000 after purchasing an additional 735,300 shares during the period. Opaleye Management Inc. grew its stake in shares of Disc Medicine by 103.1% in the 2nd quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock valued at $62,535,000 after buying an additional 434,000 shares during the period. Engineers Gate Manager LP grew its stake in shares of Disc Medicine by 110.9% in the 2nd quarter. Engineers Gate Manager LP now owns 19,552 shares of the company’s stock valued at $1,430,000 after buying an additional 10,282 shares during the period. Squarepoint Ops LLC grew its stake in shares of Disc Medicine by 139.3% in the 2nd quarter. Squarepoint Ops LLC now owns 75,872 shares of the company’s stock valued at $5,549,000 after buying an additional 44,163 shares during the period. Finally, Arizona State Retirement System increased its position in Disc Medicine by 2.4% in the 2nd quarter. Arizona State Retirement System now owns 6,844 shares of the company’s stock valued at $501,000 after buying an additional 160 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

More Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Bitopertin met the primary objective and all key goals in the Phase 3 APOLLO trial, strengthening the case that the drug could become a potential disease-modifying treatment for EPP. Disc Medicine’s rare disease drug succeeds in late-stage trial
• Positive Sentiment: Disc Medicine said it plans to resubmit bitopertin to the U.S. Food and Drug Administration, creating a significant regulatory catalyst following the successful trial. Disc Medicine’s Bitopertin Meets All Phase 3 Goals; FDA Resubmission Planned
• Positive Sentiment: The late-stage result removes a major clinical risk for IRON and drove a sharp rally as investors reassessed the commercial potential of the Roche-originated drug. Disc Medicine surges on late-stage trial win for lead asset developed with Roche
• Positive Sentiment: Bitopertin could address substantial unmet need because no disease-modifying therapy for EPP is currently approved, although the product remains investigational. Disc Medicine Says Metabolic Disorder Drug Meets Main Goal in Phase 3 Trial
• Neutral Sentiment: Disc Medicine scheduled an investor webcast to discuss the APOLLO topline data, giving investors additional details on efficacy, safety and the planned FDA filing. Disc Medicine to Host Corporate Webcast
• Negative Sentiment: Risks remain around FDA review, potential approval timing, commercialization costs and the company’s reliance on bitopertin as its primary value driver.
• Negative Sentiment: Recent reports questioned IRON’s valuation relative to book value, while disclosed insider activity showed selling and no purchases over the cited six-month period, which may weigh on sentiment. Disc Medicine Stock Still Looks Pricey As Book Value Lags Expectations

Disc Medicine Trading Up 40.6%

IRON stock traded up $23.06 during mid-day trading on Monday, reaching $79.90. The company’s stock had a trading volume of 4,133,007 shares, compared to its average volume of 589,621. Disc Medicine has a 12 month low of $40.00 and a 12 month high of $99.50. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The business’s 50 day moving average price is $71.55 and its 200 day moving average price is $71.18. The company has a market cap of $306.40 million, a price-to-earnings ratio of -12.01 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. On average, equities research analysts predict that Disc Medicine will post -6.61 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving the production of red blood cells, iron metabolism and heme biology, areas that can contribute to anemia and other blood-related complications.

Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule therapy designed to modulate glycine transporter 1 and influence heme production. The company is evaluating bitopertin in conditions including erythropoietic protoporphyria, a rare disorder associated with painful light sensitivity, as well as polycythemia vera and other hematologic diseases.

The company is also developing additional therapies intended to regulate iron availability and address anemia associated with chronic or hematologic conditions.